StockWatch
·

Vera Therapeutics, Inc. Q3 FY26 Results

VERAQ3 FY26 Results
Filing
MetricValue ($ M)
Revenue10.28
Total Income10.28
Expenditure105.98
PBT—
Net Profit-93.71
OPM—
NPM—
EPS-1.30
View full financials

Vera Therapeutics Reports Q3 2026 Financial Results and Business Updates

06 Nov 2026 · 6 Nov, 2:45 am

Summary

Vera Therapeutics reported $10.3 million in net product revenue for the third quarter of 2026, marking its first product revenue compared to zero in the prior year. The company incurred a net loss of $93.7 million, or $1.30 per share, for the quarter. The TRUTAKNA® launch is showing early momentum with significant Patient Start Forms and initial revenue, while the ORIGIN 3 trial data strengthens the clinical foundation for the drug. Management expressed excitement about the early momentum of the TRUTAKNA launch and its potential to become a foundational therapy in IgAN.

Key Highlights

  1. 1

    Vera Therapeutics reported net product revenue of $10.3 million for the third quarter ended September 30, 2026, compared to no product revenue in the prior year period.

  2. 2

    The company reported a net loss of $93.7 million, or $1.30 per share, for Q3 2026, compared to a net loss of $80.3 million, or $1.26 per share, in the prior year quarter.

  3. 3

    Research and development expenses decreased to $41.3 million in Q3 2026 from $56.5 million in the prior-year quarter due to capitalization of commercial supply manufacturing costs.

  4. 4

    Selling, general and administrative expenses increased to $61.4 million in Q3 2026 from $27.5 million in the prior year period, reflecting investment in the commercial launch of TRUTAKNA.

  5. 5

    TRUTAKNA® (atacicept-vymj) U.S. launch is building early momentum with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net product revenue in Q3.

  6. 6

    The ORIGIN 3 final efficacy analysis demonstrated stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression versus placebo through two years.

  7. 7

    Vera Therapeutics reported $384.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026.

Management Comments

M

Marshall Fordyce

We are excited by the early momentum of the TRUTAKNA launch, which exemplifies our long-standing confidence in its potential to become a foundational therapy in IgAN. Our transition to a commercial-stage company marks a new chapter for Vera, as we deliver on our commitment to people living with IgAN. We recently presented the final efficacy results from the ORIGIN 3 trial at ASN Kidney Week 2026, strengthening the clinical foundation for TRUTAKNA. The stabilization of kidney function at the physiologic rate and significant reduction in risk of composite kidney disease progression through two years reinforce the potential for TRUTAKNA to change the course of IgAN and supported our recent submission of an sBLA for full FDA approval.

M

Matt Skelton

Our team is executing on the launch priorities we established for TRUTAKNA, with growing interest from the IgAN community and approximately 700 PSFs received since launch. We are encouraged by the payer coverage policies taking shape. Our focus remains on expanding access and ensuring nephrologists have the tools and education they need to help eligible patients begin treatment with TRUTAKNA.

Informational and educational content only. Not investment advice.